Sodium nitroprusside

Cat. No.:	HY-B0564	N, /N
CAS No.:	14402-89-2	₩ //
Molecular Formula:	C _s FeN _e Na ₂ O	
Molecular Weight:	261.92	
Target:	Others	
Pathway:	Others	N O
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	Na ⁺ Na ⁺

SOLV	FNT	& SOI	
301		a 301	

		Mass Solvent Concentration	1 mg	5 mg	10 mg	
	Preparing	1 mM	3.8180 mL	19.0898 mL	38.1796 mL	
	Stock Solutions	5 mM	0.7636 mL	3.8180 mL	7.6359 mL	
		10 mM	0.3818 mL	1.9090 mL	3.8180 mL	
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.				
In Vivo		1. Add each solvent one by one: PBS Solubility: 100 mg/mL (381.80 mM); Clear solution; Need ultrasonic				
		 Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.54 mM); Clear solution 				
	,	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline)				
		Solubility: ≥ 2.5 mg/mL (9.54 mM); Clear solution				

BIOLOGICAL ACTIVITY		
Description	Sodium nitroprusside (Ro 21-2498) is a potent vasodilator working through releasing NO spontaneously in blood.	
In Vitro	Sodium nitroprusside (Ro 21-2498) is a potent vasodilator. Sodium nitroprusside has potent vasodilating effects in arterioles and venules. Sodium nitroprusside breaks down in circulation to release nitric oxide (NO). NO activates guanylate cyclase in vascular smooth muscle and increases intracellular production of cGMP. The end result is vascular smooth muscle relaxation, which allow vessels to dilate [1]. Sodium nitroprusside decreases the proliferation of vascular smooth muscle cells [2]. Sodium nitroprusside (5 mg/kg) significantly reduces the intestinal ischemiareperfusion injury as a nitric oxide donor in rats [3].	



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Chem Eng J. 15 August 2022, 136169.
- Redox Biol. 2023 Dec 18:69:103004.
- J Neuroinflammation. 2023 Feb 24;20(1):49.
- Br J Pharmacol. 2021 Aug 6.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wink, D.A., et al., The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch Biochem Biophys, 1996. 331(2): p. 241-8.

[2]. Garg, U.C. and A. Hassid, Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest, 1989. 83(5): p. 1774-7.

[3]. Namazi, H., Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia reperfusion model: a novel molecular mechanism. Clinics (Sao Paulo), 2008. 63(3): p. 405.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA